Phaseline

Companies › Shanghai Juncell Therapeutics

Shanghai Juncell Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 10 registered trials: 5 Phase 2, 5 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GC101 TIL
Autologous tumor infiltrating lymphocytes (TIL) therapy
–Phase 2Non Small Cell Lung Cancer; Melanoma; Non Small Cell Lung Cancer Metastatic; Liver CancerJan 2027
GC203 TIL
Engineered tumor infiltrating lymphocytes (TIL) with ex vivo expansion and culture
–Phase 1Solid Tumors, Adult; Solid TumorNov 2026
PD-1 antibody
PD-1 inhibitor (low-dose)
PDCD1Phase 1Solid Tumor; Perihilar Cholangiocarcinoma; Esophageal Squamous Cell Carcinoma (ESCC); Lung CancerMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06084299GC101 TILPhase 1Liver CancerOncologyAug 2026
NCT07256756GC203 TILPhase 1Solid Tumors, AdultOncologyNov 2026
NCT06473961GC101 TILPhase 1Non Small Cell Lung Cancer MetastaticOncologyJan 2027
NCT05430698PD-1 antibodyPhase 2Perihilar CholangiocarcinomaOncologyJan 2027
NCT06375187GC203 TILPhase 1Solid TumorOncologyMay 2027
NCT06375187PD-1 antibodyPhase 1Solid TumorOncologyMay 2027
NCT07560111GC101 TILPhase 2Non Small Cell Lung CancerOncologyJun 2027
NCT06703398GC101 TILPhase 2MelanomaOncologyDec 2027
NCT07559045PD-1 antibodyPhase 2Esophageal Squamous Cell Carcinoma (ESCC)OncologyJan 2028
NCT06478108PD-1 antibodyPhase 2Lung CancerOncologyDec 2028

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Binhui Biopharmaceutical Immorna Biotherapeutics CrystalGenomics PersonGen BioTherapeutics (Suzhou) ImmVira Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.